Aclaris Therapeutics

Update in progress

ACRS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for immuno-inflammatory diseases in the United States. Its pipeline includes Bosakitug (ATI-045), a Phase 2 anti-TSLP antibody for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and COPD; ATI-2138, a Phase 2a ITK/JAK3 dual inhibitor; ATI-052, a Phase 1b bispecific anti-TSLP/IL-4R antibody; ATI-9494, an oral ITK/TXK dual inhibitor; and Lepzacitinib, a soft JAK1/3 inhibitor. Founded 2012, based in Wayne, PA.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive